GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (LTS:0HIY) » Definitions » EV-to-Revenue

Atara Biotherapeutics (LTS:0HIY) EV-to-Revenue : 0.34 (As of May. 22, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Atara Biotherapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Atara Biotherapeutics's enterprise value is $67.9 Mil. Atara Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $199.7 Mil. Therefore, Atara Biotherapeutics's EV-to-Revenue for today is 0.34.

The historical rank and industry rank for Atara Biotherapeutics's EV-to-Revenue or its related term are showing as below:

LTS:0HIY' s EV-to-Revenue Range Over the Past 10 Years
Min: -3.56   Med: 4.22   Max: 301.98
Current: 0.34

During the past 13 years, the highest EV-to-Revenue of Atara Biotherapeutics was 301.98. The lowest was -3.56. And the median was 4.22.

LTS:0HIY's EV-to-Revenue is ranked better than
89.12% of 993 companies
in the Biotechnology industry
Industry Median: 7.17 vs LTS:0HIY: 0.34

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-22), Atara Biotherapeutics's stock price is $6.9614. Atara Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $22.15. Therefore, Atara Biotherapeutics's PS Ratio for today is 0.31.


Atara Biotherapeutics EV-to-Revenue Historical Data

The historical data trend for Atara Biotherapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics EV-to-Revenue Chart

Atara Biotherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 54.18 2.26 7.08 0.62

Atara Biotherapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.69 0.95 0.29 0.62 0.31

Competitive Comparison of Atara Biotherapeutics's EV-to-Revenue

For the Biotechnology subindustry, Atara Biotherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's EV-to-Revenue falls into.


;
;

Atara Biotherapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Atara Biotherapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=67.917/199.732
=0.34

Atara Biotherapeutics's current Enterprise Value is $67.9 Mil.
Atara Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $199.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics  (LTS:0HIY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Atara Biotherapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.9614/22.148
=0.31

Atara Biotherapeutics's share price for today is $6.9614.
Atara Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Traded in Other Exchanges
Address
1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics Headlines

No Headlines